Biogen's Shares Are Trading Lower On 71% Quarterly Profit Slump, Weak Tecfidera Sales
April 22, 2021 at 13:01 PM EDT
Biogen Inc reported a 70.7% fall in Q1 profit as its top-selling multiple sclerosis drug Tecfidera faced increased competition from cheaper generic drugs.
